<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:hpo ids='HP_0003473'>Myasthenia</z:hpo> gravis is an <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> marked by neuromuscular transmission failure at the neuromuscular junction </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0017531" disease_type="Disease or Syndrome" abbrv="GLNH|AFLH">Castleman disease</z:e> is a rare <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative disease</z:e> characterized by non-cancerous angiofolicular <z:mpath ids='MPATH_134'>hyperplasia</z:mpath> of lymphatic tissue </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: We describe a young man with rapid, successive manifestations of <z:hpo ids='HP_0003473'>myasthenia</z:hpo> gravis, a solitary form of <z:e sem="disease" ids="C0017531" disease_type="Disease or Syndrome" abbrv="GLNH|AFLH">Castleman disease</z:e>, <z:e sem="disease" ids="C0030809" disease_type="Disease or Syndrome" abbrv="">pemphigus vulgaris</z:e>, and anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> syndrome, which resulted in 2 ischemic cerebrovascular events that caused a severe central neurological deficit </plain></SENT>
<SENT sid="3" pm="."><plain>DISCUSSION: We were unable to find a similar case in the literature, but we hypothesize that the temporal concidence of these clinical entities may be related to a common immunological pathway, such as B-cell activation </plain></SENT>
<SENT sid="4" pm="."><plain>Therefore, we treated the patient with an <z:chebi fb="1" ids="35705">immunosuppressant</z:chebi> and <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> treatment, as well as rituximab, a monoclonal antibody therapy against CD20+ </plain></SENT>
</text></document>